Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events.
about
Automated drug screening with contractile muscle tissue engineered from dystrophic myoblastsThe role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymesIRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cellsNovel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophyBiochemical and Functional Comparisons of mdx and Sgcg(-/-) Muscular Dystrophy Mouse Models.A mathematical model of skeletal muscle disease and immune response in the mdx mouse.Regulatory interactions between muscle and the immune system during muscle regenerationGreen tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice.Extrinsic regulation of satellite cell specificationInterleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype.Nuclear factor-kappa B signaling in skeletal muscle atrophy.Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models.Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling PathwayOverexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.Secondary muscle pathology and metabolic dysregulation in adults with cerebral palsyFunctional classification of skeletal muscle networks. II. Applications to pathophysiology.Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyImplications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.Cellular mechanisms of tissue fibrosis. 4. Structural and functional consequences of skeletal muscle fibrosisWasting mechanisms in muscular dystrophy.Inhibition of prostaglandin D synthase suppresses muscular necrosis.Gene therapy in large animal models of muscular dystrophy.Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice.Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.In vitro myoblast motility models: investigating migration dynamics for the study of skeletal muscle repair.Renin-angiotensin system: an old player with novel functions in skeletal muscle.Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2.Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice.l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice.Palliative care services in families of males with Duchenne muscular dystrophy.Expression profiling of skeletal muscle in young bulls treated with steroidal growth promoters.Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy.
P2860
Q24629251-EB836D4D-E181-4E87-8E11-CF3FA363DBCBQ28076877-6AA1BE48-EAFE-4097-8827-52D9F4433C68Q28472887-17FF50EB-0C5C-4733-82CD-86F284F6476FQ28480452-697DE6BA-6B0E-44BD-B45F-A075128D2561Q30650746-02F94262-A76D-42DD-B78C-354F851D9B59Q33810272-74E42B8C-87DB-48C7-A9A1-2BBB3852C8FEQ33841066-7DB6958C-C503-4157-AEB7-6E98DD70D061Q33901041-28E95474-2227-43EA-A1E7-57A2A3F2437CQ34135241-D168DC4A-9E50-4853-8E43-4BB9CA9125B5Q34505654-F88F9D4A-0367-4201-AB0E-8BF91DE18228Q34593476-D12141FA-B807-4DA1-A1A9-A83F0AD6FA35Q34756106-B96CB1C4-8D4C-4274-971D-8FFC7078F1C0Q35388411-67297B3F-DA00-4BF4-967A-A7A557D36236Q35572589-399B3FAC-E34F-47B0-88A5-27828BD2CA2BQ35859481-9D10DBFC-207E-421B-AE7D-4265035501B8Q35928246-39F4F094-123B-40D0-9AB2-17A820160B4FQ36382552-000EE0DA-8776-46EC-8033-0BADF6C20A2AQ36530917-1AA02A4A-1CB4-4564-BABA-61502BC6C366Q36841572-22CA7723-C22D-44F4-8B87-1241018A9195Q37063632-DD3719C2-9D7A-4F2E-BE28-99A4E8285898Q37090043-4750B884-20BD-42CF-87B1-A2F0C4AF9EB2Q37093579-0437B329-2083-4C83-B5CE-6CA07BB04C93Q37138490-219BA8F0-D912-4936-A758-5CC74A557E50Q37164193-9D1AE86E-2E57-4091-8637-19F048700407Q37396408-86C4A351-5332-4A99-A577-33FBBFE47460Q37447128-718D3E87-D5CE-4829-AAA2-0AF1E68AC2D7Q37583167-34CC2C58-CBD6-415F-9EED-3C4B6D4C46F4Q38154819-BFDA15C5-0A04-4A56-BB50-BD22DEA12A2DQ38375202-C99F960B-333D-4CAC-ADC3-43AF521F6B2AQ39670210-00D8BFA3-D086-4F6F-8DDF-9E145D25E324Q41887615-F900D6CE-2EAC-4D67-A790-DCDD83B54630Q42524932-6508D4A5-1F11-49D9-AAA1-3DACA87F82A7Q43773894-4440C0EE-6265-4FE6-9929-CE59D65D38E4Q44266626-4F4882C3-4D39-45C2-A36F-208CF0338B7AQ46887832-3F9E58D8-6E20-41B5-A8B3-0386D942B5B8
P2860
Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evolving therapeutic strategie ...... : targeting downstream events.
@ast
Evolving therapeutic strategie ...... : targeting downstream events.
@en
type
label
Evolving therapeutic strategie ...... : targeting downstream events.
@ast
Evolving therapeutic strategie ...... : targeting downstream events.
@en
prefLabel
Evolving therapeutic strategie ...... : targeting downstream events.
@ast
Evolving therapeutic strategie ...... : targeting downstream events.
@en
P1433
P1476
Evolving therapeutic strategie ...... : targeting downstream events.
@en
P2093
James G Tidball
Michelle Wehling-Henricks
P304
P356
10.1203/01.PDR.0000145578.01985.D0
P407
P577
2004-11-05T00:00:00Z
P5875
P6179
1043604249